I 2- års kontrollerede kliniske forsøg med MS- patienter var infektionshyppigheden cirka 1, 5 per patient- år hos både natalizumab - og placebo- behandlede patienter.
In 2-year controlled clinical trials in MS patients, the rate of infection was approximately 1.5 per patient-year in both natalizumab- and placebo-treated patients.